Bacterial polyketide biosynthetic processes provide a wide range of structurally diverse bioactive natural products used as immunosuppressants, antibiotics, antiparasitics, growth promotants, and anticancer agents. Tremendous advances in genetic and biochemical understanding of the polyketide synthases (PKSs) and related enzymes involved in these biosynthetic processes has ushered in a new era of drug discovery in which different components of the processes can be combined or altered in order to access novel natural products. An understanding of the unique enzymes, which both provide the unusual biosynthetic precursors used in these processes, and incorporate them into a polyketide product is critical to this effort. One such example is found in ansatriemn biosynthesis where coenzyme A activated cyclohexanecarboxylic acid (CHC-CoA) is generated from a shikimate pathway intermediate, and subsequently used to generate the final antifungal polyketide product. Combining five CHC-CoA biosynthetic genes from the ansatrienin biosynthesis gene cluster of Streptomyces collznus with the avermectin biosynthetic genes in an Streptomyces a vermitilis host, has resulted in an engineered strain that produces the commercial novel antiparastic agent doramectin (an avermectin analog generated using CHC-CoA as a biosynthetic precursor). In addition to antiparasitic and antifungal agents, CHC-CoA and related compounds are important precursors used in the biosynthesis of a group of polyketide-derived protein phosphatase II inhibitors, promising antitumor agents, as well as novel functionalized antibacterial agents. The long-term objective of this application is to use the CHC-CoA biosynthetic genes and a hybrid combinatorial biosynthetic approach to generate and ultimately test the biological activity of novel members of each of these different drug classes. This objective will be accomplished through four specific aims. 1) Determination of the rate-limiting step in CHC-CoA biosynthesis and biochemical characterization of the enzymes involved in the pathway. 2) Cloning and sequencing of the biosynthetic pathway genes for formation of CHC-CoA-derived phoslactomycins, members of the important class of antitumor protein phosphatase II inhibitors. 3) Generation of new antiparasitic and antibacterial agents by using the phoslactomycin and CHC-CoA biosynthetic genes as tools to generate bacterial hosts containing hybrid polyketide synthases and CHC-CoA pathway intermediates. 4) Generation of novel protein phosphatase II inhibitors, by manipulation and combinatorial biosynthesis of the phoslactomycin biosynthetic gene cluster.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
7R01AI051629-05
Application #
7095651
Study Section
Bio-Organic and Natural Products Chemistry Study Section (BNP)
Program Officer
Korpela, Jukka K
Project Start
2002-03-01
Project End
2007-02-28
Budget Start
2005-08-01
Budget End
2006-02-28
Support Year
5
Fiscal Year
2005
Total Cost
$241,455
Indirect Cost
Name
Portland State University
Department
Chemistry
Type
Schools of Arts and Sciences
DUNS #
052226800
City
Portland
State
OR
Country
United States
Zip Code
97207
Bonnett, Shilah A; Whicher, Jonathan R; Papireddy, Kancharla et al. (2013) Structural and stereochemical analysis of a modular polyketide synthase ketoreductase domain required for the generation of a cis-alkene. Chem Biol 20:772-83
Liu, Yuan; Hazzard, Christopher; Eustáquio, Alessandra S et al. (2009) Biosynthesis of salinosporamides from alpha,beta-unsaturated fatty acids: implications for extending polyketide synthase diversity. J Am Chem Soc 131:10376-7
Eustaquio, Alessandra S; McGlinchey, Ryan P; Liu, Yuan et al. (2009) Biosynthesis of the salinosporamide A polyketide synthase substrate chloroethylmalonyl-coenzyme A from S-adenosyl-L-methionine. Proc Natl Acad Sci U S A 106:12295-300
Ghatge, Mohini S; Palaniappan, Nadaraj; Alhamadsheh, Ma'moun M et al. (2009) Application of a newly identified and characterized 18-o-acyltransferase in chemoenzymatic synthesis of selected natural and nonnatural bioactive derivatives of phoslactomycins. Appl Environ Microbiol 75:3469-76
Palaniappan, Nadaraj; Alhamadsheh, Mamoun M; Reynolds, Kevin A (2008) cis-Delta(2,3)-double bond of phoslactomycins is generated by a post-PKS tailoring enzyme. J Am Chem Soc 130:12236-7
Alhamadsheh, Mamoun M; Palaniappan, Nadaraj; Daschouduri, Suparna et al. (2007) Modular polyketide synthases and cis double bond formation: establishment of activated cis-3-cyclohexylpropenoic acid as the diketide intermediate in phoslactomycin biosynthesis. J Am Chem Soc 129:1910-1
Ghatge, Mohini; Palaniappan, Nadaraj; Das Choudhuri, Suparna et al. (2006) Genetic manipulation of the biosynthetic process leading to phoslactomycins, potent protein phosphatase 2A inhibitors. J Ind Microbiol Biotechnol 33:589-99
Ghatge, Mohini S; Reynolds, Kevin A (2005) The plmS2-encoded cytochrome P450 monooxygenase mediates hydroxylation of phoslactomycin B in Streptomyces sp. strain HK803. J Bacteriol 187:7970-6
Choudhuri, Suparna Das; Ayers, Sloan; Soine, William H et al. (2005) A pH-stability study of phoslactomycin B and analysis of the acid and base degradation products. J Antibiot (Tokyo) 58:573-82